Dr. Michael P. Waters, MD
Emergency Medicine (Emergency Medicine Physician)
751 Medical Center Ct, Department Of Emergency Medicine
Chula Vista, CA 91911
Who else practices at this address →
San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas
At a glance
- In the NPI registry since
- 2006
Licensed in California since 2005, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Emergency Medicine Physician primary
CA license A90012 (first issued 2005; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $212 in total to this clinician.
| Stryker Corporation | $168 |
|---|---|
| Antares Pharma, Inc. | $43.98 |
| Food and Beverage | $212 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 8 companies. The companies reported $522,980 in research payments for these studies, mostly to the institutions running them.
- Phase Ib trial to assess safety and tolerability of multiple subcutaneous doses of BI 3006337 in patients with overweight or obesity and hepatic steatosis
Boehringer Ingelheim International GmbH - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Ov…
Amgen Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
ModernaTX, Inc. · Completed · NCT05815498 - NB (Contrave) Cardiovascular Outcomes Trial
Currax Pharmaceuticals LLC - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A phase i/ii observer-blind, randomized, multi-center trial to evaluat
GlaxoSmithKline, LLC. - An interventional efficacy and safety phase 3 doubleblind 2ARM study to investigate orally administered ibuzatrelvir compared with placebo in nonhospitalized symptomatic adult and adolescent participants with COVID19 …
Pfizer Inc. - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in partici…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.